BioSpace News Archive

Pharming Group N.V. announced it has entered into a development collaboration and license agreement with Novartis to develop and commercialize CDZ173, a small molecule phosphoinositide 3-kinase delta (PI3Kẟ) inhibitor being developed by Novartis to treat patients with Activated Phosphoinositide 3-kinase Delta Syndrome.

An article published in Experimental Biology and Medicine describes a new class of kinase inhibitors.

A mentor is a person who has the professional experience to provide meaningful insight applicable to your situation.

Osteoporosis is a disease where the bones become more porous and fragile, which dramatically increases the risk of bone fractures. It affects about 200 million people worldwide, is a progressive disease, and there are often are no symptoms until a fracture.

Deciphera’s stock jumped from Monday’s close of $19.95 to $44.40 this morning after the company showed ripretinib provided 6.3 months of progression-free survival compared to one month from placebo.

Merck’s Keytruda has become one of the best-selling drugs in the world. Last year, it generated more than $7 billion in revenue for Merck and that is only predicted to grow, particularly as the drug wins approval for new indications.

AgriMetis, LLC is pleased to announce that Dr. Andrew Plant joined the AgriMetis team as Chief Technology Officer (CTO) in July 2019.

Ultragenyx Pharmaceutical Inc. announced that Tom Kassberg, the company’s Chief Business Officer, will present at the Wedbush PacGrow Healthcare Conference on Wednesday, August 14, 2019 at 1:20 PM ET in New York, NY.

Company continues to expand its portfolio of highly selective antibodies targeting root cause of Alzheimer’s, ALS and Parkinson’s disease

ALPN-101 Progresses to Multiple-Ascending Dose Cohorts of Phase I Study